While all of the well-known cardiovascular and renal effects of angiotensin II (ANG) are attributed to the ANG type-1 (AT 1 ) receptor, much less is known about the function of ANG type-2 (AT 2 ) receptors. This review focuses on progress made in AT 2 receptor research over the past 10 years mainly enabled by the availability of AT 2 receptor-deficient mice. Two general mechanisms regarding AT 2 receptormediated actions emerge from recent experiments. Firstly, AT 2 receptor stimulation inhibits growth and promotes apoptosis, an important mechanism during development and tissue remodeling. Secondly, ANG stimulates the release of nitric oxide (NO)/cGMP via AT 2 receptor activation, as described in the aorta, heart, and kidney. This effect appears to be indirectly mediated by the modulation of bradykinin release. Thus, activation of AT 2 receptors may be potentially protective and appears to oppose the effects mediated by AT 1 receptors. The question whether AT 2 receptors are activated in patients with elevated ANG levels when treated with AT 1 receptor antagonists and whether these effects are relevant awaits further clarification.
Introduction
Angiotensin II (ANG) as the main active peptide of the renin -angiotensin system (RAS) acts at specific G-proteincoupled receptors [1] . Based on their selective affinity for peptide and nonpeptide ligands, two ANG receptor subtypes were characterized, namely, subtype-1 (AT 1 ) and subtype-2 (AT 2 ) [2, 3] . AT 1 receptors are blocked by specific nonpeptide antagonists, such as losartan (DUP 753) and other 'sartans', while AT 2 receptor antagonists include the nonpeptide compounds PD123317 and PD123319 [1 -3] . Other AT 2 receptor ligands include the peptide agonist CGP 42112 that, however, also binds to nonangiotensin sites particularly during inflammation [1, 3, 4] . After the initial cloning of AT 1 receptors [5, 6] , AT 2 receptor cDNA was isolated by expression cloning from rat fetal tissue [7] and from the rat pheochromocytoma PC12W cell line [8] . The AT 2 receptor shares only 34% amino acid sequence homology with the AT 1 receptor.
While the role of AT 1 receptors in regulation of cardiovascular function, fluid and electrolyte homeostasis, hormone release, and drinking behavior is well established [9] , and several AT 1 receptor antagonists are now available for the treatment of hypertension, much less is known about the physiological functions of AT 2 receptors. AT 2 receptors are highly expressed in a variety of fetal tissues [10] . However, although widely distributed in the fetus, the expression of AT 2 receptors in adults is low and restricted to certain organs such as the brain, adrenal medulla, kidney, uterus, and ovary [11] [12] [13] [14] . The high expression of AT 2 receptors during fetal and early postnatal life implies an important role in cellular differentiation and organ development, and experiments using specific agonists and antagonists have provided further evidence for the involvement of AT 2 receptors in the regulation of growth, cell proliferation, and apoptosis [1] . Additionally, the observation of elevated blood pressure in AT 2 receptor-deficient mice suggested a direct or indirect role of AT 2 receptors in the control of cardiovascular and/or fluid homeostasis [15, 16] . Two AT 2 receptor gene-deficient mouse strains were generated that differ in their genetic background (FVB/N mice [15] and C57BL/6 mice [16] ). Here, we summarize current evidence for cardiovascular and renal functions of AT 2 receptors that is primarily based on recent experimental data in these mice (Table 1) .
AT 2 receptor signal transduction pathways
AT 2 receptors can couple to multiple intracellular signaling pathways depending on the cell type or cell line expressed (Fig. 1) . In cardiac myocytes, proximal tubular epithelial cells, and neuronal cells, ANG stimulates phospholipase A 2 (PLA 2 ) activity and arachidonic acid (AA) formation via AT 2 receptors [17 -19] . In cultured neurons, this effect depends on activation of inhibitory G-proteins and leads to increased delayed-rectifier K + currents (I K ) that include serine/threonine phosphatase 2A (PP2A) activation and that might reduce neuronal excitability by hyperpolarisation [19 -21] . Activation of specific protein tyrosine or serine/threonine phosphatases by AT 2 receptors is also observed in various other cell types. In rat pheochromocytoma (PC12W) and mouse fibroblast (R3T3) cell lines, AT 2 receptor-mediated growth inhibition and apoptosis involve the activation of mitogen-activated protein kinase phosphatase-1 (MKP-1) [22, 23] . In addition, ANG increases MKP-1 activity in adult rat ventricular myocytes [24] . Activation of MKP-1 and PP2A by AT 2 receptors results in an inhibition of extracellular-regulated kinases (ERK) 1 and 2 that appears to be mediated via inhibitory G-proteins [22 -27] . In N1E-115 neuroblastoma cells, AT 2 receptors inhibit ERK by a G-protein-independent mechanism that involves Src homology 2 domain phosphatase-1 (SHP-1) [28] .
The involvement of AT 2 receptors in the regulation of cellular cGMP levels by a nitric oxide (NO)-dependent pathway was initially examined in cultured bovine aortic endothelial cells [29] . Stimulation of renal AT 2 receptors increases interstitial renal cGMP levels in rats during sodium restriction by stimulation of neuronal nitric oxide synthase (NOS) and subsequent NO production that involves the release of bradykinin [30 -32] . Accordingly, in the rat aorta, ANG increases cGMP levels by stimulation of bradykinin and subsequent NO production via AT 2 receptors [33] and, in hypertrophied rat hearts, blockade of AT 2 receptors results in reduced cGMP levels that augments the growth promoting effect of AT 1 receptor stimulation [34] . Recent data also suggest the participation of NO/cGMP-and bradykininpathways in AT 2 receptor-mediated PC12W cell differentiation and in the inhibition of ANG-induced contraction of rat uterine arteries by AT 2 receptors [35, 36] .
Cardiovascular effects of AT 2 receptors
ANG regulates blood pressure by controlling vascular tone, either by enhancing smooth muscular tone or indirectly by increasing norepinephrine release, and these effects are mediated via the AT 1 receptor [37] . Moreover, neuroendocrine changes, such as activation of the hypothalamicpituitary -adrenal axis that are associated with essential hypertension, appear also to be related to AT 1 receptors [38] . Therefore, the increased basal blood pressure [16, 39] and enhanced pressure response in AT 2 receptor-deficient mice to ANG [15] and deoxycorticosterone (DOCA) -salt treatment [39] was unexpected and may be related to distinct effects in organs involved in cardiovascular regulation.
Effects mediated by the central nervous system
Earlier studies suggested the involvement of central AT 2 receptors besides that of AT 1 receptors in the regulation of Table 1 Cardiovascular and renal effects of targeted deletions of the AT 2 receptor gene
Systemic effects
Increased basal blood pressure [16, 32, 39] , C57BL/6 Increased pressure response to ANG, phenylephrine and DOCA-salt [15, 16, 32, 39, 53, 91] , FVB/N and C57BL/6
Vasculature Increased aortic AT 1 receptor expression [49] , C57BL/6 Enhanced aortic constriction by ANG [49, 50] , FVB/N, and C57BL/6 Increased vascular resistance [50] , FVB/N Delayed developmental expression of calponin and caldespon in the aorta [52] , FVB/N Vascular hypertrophy [53] , FVB/N Enhanced growth of cultured vascular smooth muscle cells [56] , FVB/N Increased coronary arterial thickening and perivascular fibrosis [57] , FVB/N Increased arterial neointima formation and smooth muscle cell proliferation after injury [58] , FVB/N Myocardium Increased cardiac AT 1 receptor expression [66] , C57BL/6 Reduced end-systolic and end-diastolic volumes and reduced heart size [66] , C57BL/6 Abolished cardiac hypertrophy and cardiac fibrosis after pressure overload or ANG-induced hypertension [68, 69] , C57BL/6 Increased cardiac hypertrophy after myocardial infarction [70, 71] , FVB/N Increased cardiac rupture after myocardial infarction [74] , C57BL/6 Reduced survival and increased left ventricular dilatation after myocardial infarction [70, 71] , FVB/N Kidney Reduced urinary sodium excretion and flow rate during chronic ANG infusion [32, 91] , C57BL/6 Reduced pressure natriuresis [88] , C57BL/6 Increased renal AT 1 receptor expression [88] , C57BL/6 Reduced levels of interstitial fluid bradykinin and cGMP [32, 91] , C57BL/6 Blunted bradykinin and cGMP response after dietary sodium restriction or chronic ANG infusion [32] , C57BL/6 Increased interstitial fluid levels of prostaglandin E 2 (PGE 2 ) and cAMP and reduced levels of PGF 2a [91] , C57BL/6 Enhanced interstitial fibrosis and less apoptotic cells after unilateral ureteral obstruction [94] , C57BL/6 Anomalies of the urinary tract resembling human congenital anomalies [93] , C57BL/6 Reduced apoptosis during development of the ureter [93] , C57BL/6
Listed are effects seen in the AT 2 receptor-deficient mice when compared with wild-type mice.
drinking behavior and vasopressin release from the hypothalamus [40 -43] . In one study, AT 2 receptor activation by ANG seemed to oppose the AT 1 receptor-mediated stimulation of water intake and vasopressin release [41, 42] , while others rather showed similar action of both receptor subtypes [40] . Studies in ANG receptor-deficient mice suggest a synergistic effect of AT 1 and AT 2 receptors regarding ANG-induced water intake [15] . The participation of AT 2 receptors in the mediation of hypothalamic ANG effects on hormones was supported by the detection of AT 2 receptors in the paraventricular nucleus of the mouse hypothalamus where both AT 1 and AT 2 receptors are present [43] .
Recent data suggest a role of central AT 2 receptors in the suppression of baroreflex sensitivity by showing an increased baroreceptor sensitivity and decreased blood pressure variability in AT 2 receptor-deficient mice [44] . In rats, ANG was also shown to suppress the baroreceptor reflex via, at least in part, AT 2 receptors when injected into the ventral or rostral medulla oblongata [45, 46] . However, other authors found only AT 1 receptors to suppress the sensitivity of the baroreceptor reflex [47] . Centrally applied ANG increased systolic blood pressure to a greater extent in AT 2 receptor-deficient mice than in wild-type mice, and this effect was also blocked by an AT 1 receptor antagonist, but was amplified by the AT 2 receptor antagonist PD123319 in wild-type mice [48] . These data suggest depressor actions of central AT 2 receptors that appear to oppose the pressure response to ANG-mediated via AT 1 receptors. In contrast, the increased baroreceptor sensitivity in AT 2 receptor-deficient mice [44] would in fact suggest decreased blood pressure in these animals. On the other hand, the elevated blood pressure that was observed in AT 2 receptor-deficient mice [16, 39] could be caused by various peripheral mechanisms, and it seems likely that in these mice the increased baroreceptor sensitivity reflects rather adaptational changes.
Thus, brain AT 2 receptors may play a crucial role in the regulation of blood pressure. However, besides a central regulation of blood pressure via AT 2 receptors, cardiovascular and renal effects may also possibly contribute to the elevated blood pressure in AT 2 receptor-deficient mice. 
Direct vascular effects
Deletion of the AT 2 receptor gene causes an increase in aortic contractility [49, 50] which is accompanied by an increased expression of AT 1 receptors [49] . Thus, the enhanced acute pressure response to ANG in AT 2 receptor-deficient mice may be in part mediated by an increased AT 1 receptor expression. However, because the difference in diastolic blood pressure between wild-type and AT 2 receptor knockout mice persisted after AT 1 receptor blockade with losartan [16] and because the AT 2 receptor expression is very low in the adult cardiovascular system, it seems that during development, the AT 2 receptor also exerts long-term effects on the vascular structure. In the rat aorta, the expression of AT 2 receptors is up-regulated at the late gestational phase and rapidly declines after birth to very low levels in adult animals [51] . Therefore, the involvement of AT 2 receptors in vascular development and growth was proposed. Accordingly, the expression of calponin and h-caldesmon, cytoskeleton-associated actinbinding proteins and markers of smooth muscle differentiation, was significantly delayed in AT 2 receptor-deficient mice suggesting that AT 2 receptors promote the differentiation of vascular smooth muscle cells [52] . Furthermore, in fetal vascular smooth muscle cells, AT 2 receptor activation seems to oppose the action of AT 1 receptors and enhances apoptosis, an effect that is mediated by activation of the tyrosine phosphatase SHP-1 [27] . A more recent study demonstrated an increased pressure response to ANG and the a 1 -receptor agonist phenylephrine in vivo and an augmented vasoconstriction of femoral arteries from AT 2 receptor-deficient mice not only in response to ANG, but also to norepinephrine and K + -depolarization [53] . This increased vasoconstriction was accompanied by hypertrophy of the media caused by an increase of vascular smooth muscle cells.
A significant role of AT 2 receptors in tissue remodeling was also observed after vascular balloon injury. When balloon-injured rat carotid arteries were transfected with the AT 2 receptor gene in vivo, the formation of the neointima was significantly reduced [54] . This effect was blocked by treatment with the AT 2 receptor antagonist PD 123319. Moreover, transfection of cultured rat vascular smooth muscle cells with the AT 2 receptor gene reduced AT 1 receptor-mediated cell proliferation in response to ANG [54] and facilitated apoptosis, an effect that was inhibited by AT 1 receptor stimulation [55] . Thus, AT 2 receptor-mediated effects of ANG seem to be antiproliferative and may counter-regulate growth-stimulating actions mediated by AT 1 receptors. These findings were recently supported by studies in AT 2 receptor-deficient mice showing enhanced growth of cultured vascular smooth muscle cells [56] and increased coronary vascular remodeling and perivascular fibrosis after aortic banding [57] in the absence of AT 2 receptors. Furthermore, in AT 2 receptor-deficient mice, the formation of the neointima and the proliferation of smooth muscle cells were greater than in wild-type mice after injury of the femoral artery [58] .
As a consequence of AT 2 receptor stimulation by elevated ANG levels during AT 1 receptor blockade, the kininkallikrein system may be activated [59] . Gohlke et al. [33] reported an increased release of aortic cGMP after acute ANG treatment that was blocked by the AT 2 receptor antagonist PD 123319. This AT 2 receptor effect was abolished by bradykinin B 2 receptor blockade as well as by inhibition of nitric oxide synthase. Because cGMP levels were also increased by treatment with losartan and because PD 123319 affected the increase in cGMP levels after ANG/ losartan treatment, it was concluded that AT 1 receptor blockade stimulates aortic cGMP release by activation of AT 2 receptors. ANG at low concentrations inhibits NO production and endothelium-dependent NO-mediated vasodilatation of porcine coronary arteries via AT 1 receptors and superoxide production [60] . At higher concentrations, this effect seems to be antagonized by vasodilatory effects via AT 2 receptor activation [60] . Thus, ANG might exert opposite effects via AT 1 and AT 2 receptors that might involve the kinin/NO pathway.
Cardiac-specific effects
In the human heart, AT 2 receptors are the main subtype whereas, in rodents the AT 2 receptor expression is low [61] . Moreover, cardiac AT 2 receptors are up-regulated in rats and humans under certain pathophysiological conditions, such as myocardial infarction, and are therefore suggested to play an essential role in tissue remodeling [62, 63] . In hypertrophy of adult rat hearts, the growth response of the left ventricle to ANG was enhanced by blockade of AT 2 receptors [34] . Cardiac-specific overexpression of the AT 2 receptor gene in mice reduced the AT 1 receptor-mediated enhancement of heart rate and blood pressure [64] . This effect was completely blocked with an AT 2 receptor antagonist. In addition, left ventricular systolic function was preserved after reperfused myocardial infarction in these mice [65] . As in the vasculature, increased levels of AT 1 receptor mRNA were found in the left ventricles of AT 2 receptor-deficient mice [66] . Studies in cultured cardiomyocytes indicate an interaction of AT 1 and AT 2 receptors in the promotion of apoptosis that might be important for tissue remodeling [67] .
AT 2 receptor-deficient mice showed smaller end-systolic and end-diastolic volumes in association with a reduced heart size compared to wild-type mice, but no other changes in left ventricular performance were observed [66] . In AT 2 receptor-deficient mice, inconsistent results exist regarding cardiac hypertrophy. In one model, deletion of the AT 2 receptor prevented left ventricular hypertrophy and interstitial fibrosis after pressure overload or in the case of ANGinduced hypertension and a stimulatory effect of AT 2 receptors in cardiac hypertrophy was concluded [68, 69] . On the other hand, AT 2 receptor-deficient mice with the FVB/N background acquired greater left ventricular hypertrophy after myocardial infarction than wild-type mice [70, 71] . Cardiac-specific overexpression of the AT 2 receptor was shown to either reduce perivascular fibrosis in mice treated with ANG for 14 days [72] or to increase fibrosis and heart failure [73] . Thus, various factors, such as experimental settings, sufficient AT 2 receptor expression/ stimulation, and the genetic background of mice, may contribute to the observed different effects on cardiac hypertrophy attributed to AT 2 receptors.
After myocardial infarction, the incidence of death by cardiac rupture and the levels of prostaglandin E 2 were increased, while fibrosis and collagen expression were reduced in AT 2 receptor gene-deficient mice when compared to wild-type mice [74] . Furthermore, AT 2 receptordeficient mice showed reduced survival and impaired cardiac function after myocardial infarction when compared to wild-type mice [70, 71] . In contrast, Xu et al. [75] found no difference in the survival rate and cardiac function after myocardial infarction between AT 2 receptor-deficient and wild-type mice but found an improved therapeutic effect of an AT 1 receptor antagonist. Interestingly, chronic heart failure after myocardial infarction is similar in mice with or without functional eNOS, but advantageous effects of AT 1 receptor antagonists are diminished in eNOS-deficient mice [76] . As in this situation, AT 2 receptors may be stimulated by increasing ANG levels; they may stimulate kinin/NO release and may, by this means, contribute to beneficial effects of AT 1 receptor antagonists. In a rat model with chronic heart failure, left ventricular remodeling and cardiac function were improved by blockade of AT 1 receptors [77] . This effect was inhibited by treatment with an AT 2 receptor antagonist and also, in part, by treatment with a bradykinin B 2 receptor antagonist. In pigs, infarct size was reduced after regional myocardial ischemia by blockade of the AT 1 receptor, and this reduction was abolished by pretreatment with the AT 2 receptor antagonist PD 123319 and by blockade of B 2 receptors [78] . The aforementioned reduction of perivascular fibrosis by overexpressed cardiac AT 2 receptors after pressure overload was abolished after blockade of the B 2 receptors or NO synthase [72] . Thus, as in the vasculature, the myocardial kinin/NO system appears to be involved in AT 2 receptor-mediated effects. Bradykinin, as the main peptide of the kinin-kallikrein system, is known to comprise cardioprotective actions which are mediated via the B 2 receptor [59] . The role of NO in antihypertrophic effects of AT 2 receptors is supported by recent data showing the capacity of ANG to increase myocardial eNOS gene expression via AT 2 receptors [79, 80] . Furthermore, in AT 2 receptor-deficient mice, cardiac eNOS expression and cGMP levels were lower than in wild-type mice, and myocardial injury that is followed by hypertrophy results in increased cardiac eNOS expression in wild-type but not in AT 2 receptor-deficient mice [80] .
Renal effects of AT 2 receptors
In the kidney of adult rodents and humans, AT 2 receptor levels are very low in contrast to the highly expressed AT 1 receptor [81 -83] . In adult humans, renal AT 2 receptors have been found only on large cortical blood vessels [83] . In kidneys of fetal and newborn rats, mice, and humans, however, AT 2 receptor levels are as high as in other tissues during development [81 -83] , and in adult rats AT 2 receptors are reexpressed on glomeruli and in interstitial cells during dietary sodium depletion [82] .
Renal actions of ANG include the stimulation of vasoconstriction and tubular sodium reabsorption, effects attributed to AT 1 receptors. Because of the low amounts of AT 2 receptors in the adult kidney, functional analysis of AT 2 receptors is difficult to carry out, and the results reported are controversial. ANG-induced renal vasoconstriction was found to be increased in rabbit afferent arterioles [84] or decreased in renal microvessels of rats [85] by the AT 2 receptor antagonist PD123319. In rats, AT 2 receptor antagonists increased and agonists decreased diuretic and natriuretic effects of high renal perfusion pressure [86, 87] . The diuretic and natriuretic actions of renal AT 2 receptors are emphasized by the reduced pressure natriuresis in AT 2 receptor-deficient mice [88] . In contrast, the diuresis and natriuresis induced by the AT 1 receptor antagonist losartan was partly blunted by the AT 2 receptor antagonist PD 123319 in spontaneously hypertensive rats [89] . Interestingly, the renal effects of AT 1 receptor blockade in this model were also attenuated with icatibant (Hoe 140), a bradykinin B 2 receptor antagonist, and by the cyclo-oxygenase inhibitor meclofenamate [89] .
In a series of experiments, Siragy and Carey [31] analyzed the function of renal AT 2 receptors using a microdialysis technique. During sodium depletion, ANG stimulated the release of renal cGMP via AT 2 receptors by increasing nitric oxide. AT 2 receptor-deficient mice showed a more pronounced decrease in sodium excretion in response to chronically infused ANG that was associated with markedly decreased levels of renal bradykinin and cGMP compared to wild-type animals [32] . Furthermore, AT 2 receptor-deficient mice did not respond to sodium depletion with an increase in renal bradykinin and cGMP [32] . These AT 2 receptor actions were mediated by the production of bradykinin and nitric oxide/cGMP [90] . In addition, AT 1 receptor-mediated production of renal prostaglandin E 2 was enhanced by the AT 2 receptor antagonist PD 123319 [30] . These results were also confirmed in AT 2 receptor-deficient mice [91] , whereas similar experiments in B 2 receptordeficient mice also indicate the possibility of direct stimulation of NO synthesis by AT 2 receptor activation [92] . Thus, AT 2 receptor stimulation opposes AT 1 receptor-mediated antinatriuretic effects of ANG in the kidney and a protective role of renal AT 2 receptors was proposed.
AT 2 receptors-deficient mice develop an obstructive nephropathy that resembles congenital anomalies of the kidney and urinary tract in humans [93] . The development of this phenotype is accompanied by a reduced apoptotic activity around the ureter of AT 2 receptor-deficient mice at 16.5 gestational days. Moreover, a significant incidence of a mutation in the AT 2 receptor gene occurs in human infants with congenital kidney and urinary tract anomalies [93] . Thus, AT 2 receptors play an important role for the ontogenesis of the kidney and ureter. Complete unilateral ligation of the ureter results in a more severe fibrosis in AT 2 receptordeficient mice as indicated by analyzing the numbers of fibroblasts and myofibroblasts [94] . While the degree of cell proliferation was similar in wild-type and AT 2 receptordeficient mice, the number of apotopic cells was lower in the AT 2 receptor-deficient mice. Accordingly, blockade of AT 2 receptors with PD 123319 inhibited apoptosis and enhanced fibrosis in kidneys with a unilateral ureteral obstruction [95] . The antifibrotic AT 2 receptor-mediated effects seem to oppose the profibrotic ANG actions by AT 1 receptor stimulation.
Summary and outlook
Although ANG actions regulating blood pressure were mainly attributed to AT 1 receptors, there is convincing evidence that AT 2 receptors are also involved at cardiovascular and renal levels. AT 2 receptors seem to functionally antagonize ANG actions mediated by AT 1 receptors. Because blockade of AT 1 receptors increases the plasma levels of ANG, treatment with AT 1 receptor antagonists may lead to AT 2 receptor stimulation. Therefore, understanding of the details of AT 2 receptor-mediated effects is of great importance. The questions whether AT 1 and AT 2 receptors are colocalized at the cellular level and which exact mechanisms mediate a possible AT 1 -AT 2 receptor crosstalk still remain open.
Two general concepts regarding the mechanisms of AT 2 receptor actions emerge from experimental data during the past 10 years that were also confirmed using AT 2 receptordeficient mice. Firstly, ANG regulates growth and apoptosis via the AT 2 receptor. Secondly, in the aorta, heart, and kidney, AT 2 receptor activation stimulates the release of nitric oxide/cGMP and may mediate vascular relaxation. This effect could be indirectly mediated by the modulation of bradykinin release. Thus, a main physiological role of AT 2 receptors appears to be the inhibition of cell proliferation and the propagation of cell differentiation during tissue development. In the adult, these AT 2 receptor actions seem to be reactivated throughout structural tissue remodeling. By increasing apoptosis and inhibiting growth, AT 2 receptors may counter-regulate the growth-stimulating ANG effect mediated by AT 1 receptors. However, at present, it is unclear whether AT 2 receptor-mediated effects in selected tissues/ cell lines and diverse experimental settings could be generalized. In addition, the question whether AT 2 receptor activation is relevant and of beneficial use in patients treated with AT 1 receptor antagonists remains to be clarified in the future.
